STOCK TITAN

Equillium (EQ) Stock Price, News & Analysis

EQ NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
91 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
+25.2% close of December 11, 2025
1-year change
+53.6% closing prices, November 13, 2025 to November 13, 2026
1-month change
-2.3% closing prices, October 13, 2026 to November 13, 2026

Company Description

Equillium, Inc. (Nasdaq: EQ) is a clinical-stage biotechnology company focused on developing novel therapies to treat severe autoimmune and inflammatory disorders. According to the company’s public disclosures, Equillium leverages a deep understanding of immunobiology and immuno-inflammatory pathways to advance a pipeline of immunomodulatory assets and a product platform targeting conditions with high unmet medical need.

Equillium is based in La Jolla, California and its common stock trades on the Nasdaq Capital Market under the symbol EQ, as noted in multiple SEC filings. The company operates in the pharmaceutical preparation manufacturing and broader biotechnology space, with an emphasis on immune-mediated diseases where dysregulated inflammation plays a central role.

Core focus and therapeutic pipeline

Public statements describe Equillium’s pipeline as consisting of novel immunomodulatory assets and a product platform aimed at key immuno-inflammatory pathways. The company has highlighted EQ504 as its lead therapeutic candidate. EQ504 is described as an investigational, potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other anti-inflammatory and immunomodulatory agents.

Equillium’s disclosures explain that AhR is critical to barrier organ tissue physiology and immunology. Modulating AhR is described as maintaining barrier function, promoting tissue repair and regeneration, and regulating resident immune cells with anti-inflammatory responses. EQ504’s preclinical properties are stated to provide the potential for targeted, local delivery, including enteric-coated oral formulations for the treatment of ulcerative colitis and pouchitis, and inhaled formulations for inflammatory lung or pulmonary diseases.

In addition to EQ504, earlier descriptions of Equillium’s pipeline reference several novel immunomodulatory assets and a product platform, as well as historical clinical and pre-clinical product candidates such as itolizumab (EQ001), EQ101 and EQ302. Itolizumab has been described as an anti-CD6 immune-modifying monoclonal antibody that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells. The company has disclosed that it terminated collaboration and license agreements related to itolizumab with Biocon Limited, with licenses reverting to Biocon.

Equillium’s recent communications emphasize a sharpened focus on advancing EQ504 into the clinic. The company has hosted key opinion leader events discussing the role of AhR in intestinal inflammation, the unmet medical need in ulcerative colitis (UC), and the potential clinical utility of EQ504 as a novel oral, colon-targeted therapeutic. Public materials describe EQ504 as having broad therapeutic potential in UC, including potential use as a standalone oral therapy or in combination with other therapeutic approaches, and as a candidate for pouchitis and inflammatory lung or pulmonary diseases.

Company descriptions highlight EQ504’s multi-modal, non-immunosuppressive mechanism, including selective activation of anti-inflammatory and tissue-regenerative pathways. Preclinical data discussed in company events and releases describe features such as enhancing IL-10 and IL-22 signaling, supporting regulatory T-cell function, and protecting epithelial barrier integrity, all framed within the broader concept of AhR modulation in immune-mediated diseases.

Strategic and financial positioning

Equillium has disclosed a range of corporate and financing activities that support its development plans. These include a private placement financing designed to provide up to $50 million in gross proceeds, with an initial tranche intended to fund operations for an extended period and to support the advancement of EQ504 into a Phase 1 clinical study. The company has also used at-the-market offering mechanisms and other equity financing tools, as detailed in its Form 8-K filings and prospectus supplements.

Regulatory filings note that Equillium has experienced significant operating losses and negative cash flows from operations, with auditors including a going concern paragraph in prior annual reports. In response, the company has described operating changes to decrease expenditures and conserve cash, alongside capital-raising transactions and pipeline prioritization, particularly around EQ504.

Cryptocurrency treasury reserve strategy

In addition to its biotechnology activities, Equillium has publicly announced a cryptocurrency treasury reserve strategy as part of its broader financial and growth objectives. The company has amended its investment policy to authorize the purchase of cryptocurrency and has described this strategy as intended for diversification, liquidity and long-term capital appreciation potential. At the time of the relevant disclosures, Equillium indicated that it had not yet purchased cryptocurrency but intended to actively pursue opportunities to implement this strategy, while continuing to prioritize development of EQ504.

Regulatory and corporate governance disclosures

Equillium regularly files Form 8-K reports and other SEC documents covering topics such as:

  • Changes in its independent registered public accounting firm, including dismissal of KPMG LLP and engagement of Crowe LLP.
  • Board and senior leadership updates, including director resignations, committee changes and officer appointments.
  • Termination of collaboration and license agreements related to itolizumab with Biocon Limited, and associated technical service arrangements.
  • Equity financings, private placements, and at-the-market offering arrangements.
  • Notices from The Nasdaq Stock Market LLC and subsequent regaining compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Capital Market.

These filings provide investors with details on Equillium’s capital structure, governance, risk factors and other material events that may affect the company’s operations and financial condition.

Position within the biotechnology sector

Within the broader pharmaceutical preparation manufacturing and biotechnology sector, Equillium positions itself as a biotechnology innovator focused on severe autoimmune and inflammatory disorders. Its emphasis on AhR modulation and immuno-inflammatory pathways reflects a strategy centered on immune system regulation and barrier organ health, particularly in gastrointestinal and pulmonary contexts. The company’s disclosures consistently reference high unmet medical need in the diseases it targets and describe a pipeline and platform oriented around immunomodulation.

Summary

According to its public statements and regulatory filings, Equillium, Inc. is a Nasdaq-listed, La Jolla–based clinical-stage biotechnology company concentrating on immunobiology-driven therapeutics for severe autoimmune and inflammatory disorders. Its lead candidate EQ504, an investigational AhR modulator, and its broader immunomodulatory platform are central to its development plans. Alongside its core biotech activities, the company has also outlined a cryptocurrency treasury reserve strategy as part of its financial planning, while using equity financings and cost management to support ongoing operations and clinical development objectives.

Stock Performance

$1.27
-1.55%
-0.02
Pre-marketLast updated: November 16, 2026 at 04:11
+53.6%
Performance 1 year
$104.6M

Equillium (EQ) closed at $1.29 on November 13, 2026. Over the past 12 months, the price has gained 53.6%.

See what a $1,000 investment in EQ would be worth today

Average down calculator for EQ

EQ Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

Equillium reported operating income of -$23.6M in FY2025, and net income was -$22.4M. Diluted earnings per share stood at -$0.39. The company generated -$22.7M in operating cash flow. The current ratio was 10.58, measuring current assets divided by current liabilities.

-$22.4M
Net Income (FY2025)
-$22.7M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

NOV
17
November 17, 2026 - November 19, 2026 Marketing

Jefferies meetings

One-on-one investor meetings at Jefferies Global Healthcare Conference in London, Nov 17–19, 2026; meetings for registered investors.
JAN
30
January 30, 2027 Corporate

25% options vest

25% of 59,750 inducement options vest under 2024 Inducement Plan
JAN
30
January 30, 2027 - January 30, 2030 Corporate

Remaining options vest monthly

Remaining 75% vests monthly over 36 months, completing on 2030-01-30
Q2
2027
Q2 2027 Clinical

Topline data release

Expected topline results from EQ504 Phase 1 SAD/MAD study approximately six months after Q4 2026 start; webcast possible.
APR
01
April 1, 2027 Corporate

25% option vesting

8,000 shares vest under inducement option granted 2026-04-01
APR
01
April 1, 2027 - April 1, 2030 Corporate

Monthly option vesting period

Remaining 24,000 shares vest monthly over 36 months; grant date 2026-04-01
Q2
2027
Q2 2027 Clinical

Proof-of-mechanism data

Phase 1 EQ504 proof-of-mechanism data expected in Q2 2027 from ~70 healthy participants; topline timing only.
MAY
01
May 1, 2027 Corporate

25% vesting date

25% of 800,000 options (200,000) vest on 2027-05-01; exercise price $2.08; subject to continued service.
MAY
2027
May 2027 Clinical

Phase 1 topline data

Topline Phase 1 proof-of-mechanism data for EQ504 anticipated ~six months after study initiation (around May 2027).
H2
2027
H2 2027 Clinical

Proof-of-concept start

Planned start of placebo-controlled proof-of-concept trial in moderately to severely active ulcerative colitis in H2 2027, subject to Phase 1.
H2
2027
H2 2027 Clinical

Ulcerative colitis study

Subject to supportive Phase 1 results, Equillium plans an ulcerative colitis proof-of-concept study in H2 2027; details TBD.
H2
2027
H2 2027 Clinical

Ulcerative colitis trial

Planned start of placebo-controlled ulcerative colitis study in H2 2027, contingent on supportive Phase 1 EQ504 results.
MAY
01
May 1, 2030 Corporate

Final vesting completion

Remaining 75% (600,000) vests monthly over 36 months through 2030-05-01; exercise price $2.08; subject to service.

Equillium has 13 upcoming scheduled events. The next event, "Jefferies meetings", is scheduled for November 17, 2026 (tomorrow). Investors can track these dates to stay informed about potential catalysts that may affect the EQ stock price.

Short Interest History

Last 12 Months

Short interest in Equillium (EQ) currently stands at 5.9 million shares, up 4.7% from the previous reporting period, representing 11.1% of the float. Since November 2025, short interest has increased by 669.1%.

Days to Cover History

Last 12 Months

Days to cover for Equillium (EQ) currently stands at 9.5 days, down 13.1% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 393.3%. Across the settlements charted above, it has ranged from 1.0 to 15.0 days.

EQ Company Profile & Sector Positioning

Equillium (EQ) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing EQ often look at related companies in the same sector, including Minerva Neurosciences, Inc (NERV), Kazia Therapeutics Limited (KZIA), Spruce Biosciences, Inc. (SPRB), Cue Biopharma, Inc. (CUE), and Adagene Inc. (ADAG). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate EQ's relative position within its industry.

Frequently Asked Questions

The current stock price of Equillium (EQ) is $1.27 in pre-market trading as of November 16, 2026.

The market cap of Equillium (EQ) is approximately $104.6M. Learn more about what market capitalization means .

The FY2025 net income of Equillium (EQ) is -$22.4M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Equillium (EQ) is -$0.39 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Equillium (EQ) is -$22.7M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Equillium (EQ), current assets divided by current liabilities, was 10.58 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Equillium (EQ) is -$23.6M for FY2025, its most recent completed fiscal year. Learn about operating income.

Equillium, Inc. is a clinical-stage biotechnology company that, according to its public statements, develops novel therapeutics to treat severe autoimmune and inflammatory disorders. The company focuses on immunobiology and immuno-inflammatory pathways to advance a pipeline of immunomodulatory assets and a product platform.

EQ504 is Equillium’s lead therapeutic candidate, described as an investigational, potent and selective aryl hydrocarbon receptor (AhR) modulator. Company materials state that it has a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other anti-inflammatory and immunomodulatory agents, with potential for targeted local delivery in ulcerative colitis, pouchitis and inflammatory lung or pulmonary diseases.

Equillium’s disclosures emphasize severe autoimmune and inflammatory disorders, with a particular focus on ulcerative colitis and related gastrointestinal conditions such as pouchitis. The company has also referenced potential applications of its lead candidate EQ504 in inflammatory lung or pulmonary diseases.

Equillium’s common stock is listed on the Nasdaq Capital Market under the ticker symbol EQ, as noted in multiple Form 8-K filings and other regulatory disclosures.

SEC filings list Equillium’s principal offices in La Jolla, California. The company’s address information appears in several Form 8-K reports filed with the U.S. Securities and Exchange Commission.

Equillium describes its approach as leveraging a deep understanding of immunobiology to develop immunomodulatory therapies that target immuno-inflammatory pathways. In the case of EQ504, this includes modulation of the aryl hydrocarbon receptor (AhR), which the company states is critical to barrier organ tissue physiology, barrier function, tissue repair and regulation of resident immune cells with anti-inflammatory responses.

Company filings report that on September 30, 2025, Equillium and Biocon Limited entered into a termination agreement that ended their collaboration and license agreements related to itolizumab. All licenses granted by Biocon to Equillium under those agreements, including with respect to itolizumab, terminated and reverted to Biocon, and Equillium agreed to provide certain technical services in connection with the transition.

Equillium has disclosed several financing activities, including a private placement structured to provide up to $50 million in gross proceeds and at-the-market equity offerings under an Open Market Sale Agreement. The company has stated that it expects net proceeds from these financings, together with existing cash and cash equivalents, to support its operations and the development of EQ504 for an extended period, subject to assumptions and risks outlined in its filings.

In an 8-K filing and related press release, Equillium announced that it amended its investment policy to authorize the purchase of cryptocurrency as a treasury reserve strategy. The company describes this as part of its broader financial and growth objectives, citing diversification, liquidity and long-term capital appreciation potential, while noting that it had not yet purchased cryptocurrency at the time of the disclosure and that it continues to pursue its biotech mission.

An 8-K filed on August 29, 2025 reports that Equillium received notice from the Nasdaq Listing Qualifications Department that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued inclusion on the Nasdaq Capital Market. The company had previously disclosed non-compliance and an additional compliance period before meeting the requirement.